A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q

Trial Profile

A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk MDS and AML With Del 5q

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms GFM-Chimio-Rev
  • Most Recent Events

    • 23 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Dec 2015.
    • 23 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jun 2015 to 1 Dec 2015.
    • 23 Apr 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jan 2015 to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top